Future of the Current Anticoronaviral Agents!

“

In general, for almost 100% effective management and treatment of any coronaviral infection, the three principal phases of infection (the entry, multiplication, and pathogenic phases) should be successfully targeted by a combination therapy or, at least, a very potent multitarget monotherapy. Targeting only any one or two phases of the three, though effective, could not provide more than 85% successful control of the infection at most, along with the possibility of prolonging the primary treatment interval from very few days (in the case of the triple-target therapy) to some weeks. Many natural compounds have shown very promising anticoronaviral activities, rendering them ideal drug candidates to be included in the therapeutic management protocols in the next similar coronaviral pandemics. Examples of these drugs are riboprine, thymoquinone, cordycepin, quercetin, luteolin, curcumin, bromelain, and vitamin D. Ensitrelvir fumarate, on the other hand, could be considered the most promising clinically-effective synthetic anticoronaviral agent (up to date) that may be highly efficient against the imminent invasions of the newer coronavirus species (if any). The available anticoronaviral remedies are provided in different types of formulations, e.g., oral, intravenous, subcutaneous, and nasal-spray, allowing for broad and unrestricted use of these therapies in all ages/conditions and at all levels. Continuing to track the coronaviral particles deeply in the diverse human tissues and organs, along with monitoring all scientifically-unexplained effects of the virus at the molecular, cellular, and extracellular levels, is very important to reveal the remaining mysterious secrets of the coronavirus species (including the next species) and also to potentially provide novel therapeutic targets against the virus.

”